Exploratory Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247, Beijing YSCell Biotech Co., Ltd. [Abbreviated as YS])in Patients With Recurrent or Progressive Glioblastoma

NCT07678138 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Glioblastoma

Interventions

BIOLOGICAL: Neoantigen DC Vaccine (YS247) for Glioblastoma

Sponsor

Huanhu Hospital Affiliated to Tianjin Medical University